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5Foreword 
My interest in this area started when I undertook three months practical training in clinical 
pharmacy for the specialist in hospital pharmacy degree. After completing the degree there 
were no positions for clinical pharmacists in Norway, so I left hospital pharmacy and entered 
the field of drug utilisation. Finally, in 1998 the chief pharmacist called me back to start a 
small clinical pharmacy service at the medical department of Lovisenberg Diakonale hospital. 
I started with just a few hours per week on the ward and I really enjoyed it.  
LOOK (Local Oslo group of clinical pharmacists) was started in 1998 by the four 
pioneers that held positions as clinical pharmacists in the Oslo hospitals. Throughout the years 
LOOK has been an important and supportive discussion forum for our clinical work. It was in 
this forum the first idea of a clinical pharmacy project was born.  
I have always been fascinated by ice: 
In early childhood – when I was sailing ice-floes in the Oslo fjord; 
In young age – when seeking challenges at Svalbard and at the ice edge by the North Pole; 
when skiing crosswise on glaciers and watching the glacier calve; 
And now, being older and captured by the fascination of my profession,  
I am excited of the iceberg as a metaphor. 
Drug-related problems could be described as an iceberg. Adverse drug reactions – the ice above the water 
surface – being the overt problems felt by the patients. Underneath the surface – the main part of the iceberg –
we find drug-related problems that might lead to disease and disaster.
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8“Errare humane est” 
Using drugs can be compared to using Damocles two-edged sword: there is a fine balance 
between good and evil – that is, between the wanted and the unwanted effects of a drug. The 
challenge is to find the optimal line where the effects are good and the unwanted effects are 
acceptable.   
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Abbreviations, Definitions and Explanations
Abbreviations
ACE   Angiotensin-converting enzyme 
ADR    Adverse Drug Reaction 
ATC   Anatomical Therapeutic Chemical 
DDI   Drug interactions 
DRP   Drug-related problem 
DRUID  The internet-based Norwegian Drug Information Database 
GFR   Glomerular filtration rate 
MDRD  Modification of Diet in Renal Disease  
NSAID  Non-steroidal anti-inflammatory drug 
RI   Renal impairment 
SCr   Serum creatinine 
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Definitions and explanations
Adverse drug reaction (ADR) Any noxious, unintended, and undesired effect of a drug, 
which occurs at doses used in humans for prophylaxis, 
diagnosis, or therapy (1). This definition excludes 
therapeutic failures, intentional and accidental poisoning, 
and drug abuse. The related term Adverse Drug Events 
(ADE) is an injury resulting from the use of a drug. This 
term also includes errors in administration. 
Anatomical Therapeutic Chemical  A drug classification system embraced by the WHO  
classification system to be used in pharmacoepidemiological studies, 
administered by the WHO Collaborating Centre for Drug 
Statistics Methodology in Oslo, Norway (2). 
Clinical/pharmacological risk factor Factors acknowledged to increase the risk of DRPs 
arising.  In this work these are: polypharmacy, reduced 
renal function, reduced liver function, diabetes mellitus, 
cardiac failure, allergy, non-compliance, earlier reported 
ADR and other factors that may affect the patient’s 
taking the drugs used. 
Cockcroft-Gault equation Estimated creatinine clearance (Cr.Cl.)(ml/min)= 
(140-age) x weight (in kg) x constant
             SCr (in micromol/l) 
Constant: 1.23 for men and 1.04 for women 
Adjustments: Cr.Cl. per 1.73 m2 body surface: Cr.Cl. x 1.73/body 
surface. Body surface = 0,20247 x height (m) 0,725 x weight 0,425
(3).
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Drug interaction (DDI) An interaction is defined as occurring when the effects of 
one drug are changed by the presence of another drug, 
food, drink or some environmental chemical agent (4). 
Drug-related problem (DRP) An event or circumstance involving drug therapy that 
actually or potentially interferes with desired health 
outcomes (5). See also M-DRP and P-DRP. 
Drug risk ratio The number of DRPs associated with a drug (or a drug 
group) in relation to the number of times the drug (or 
drug group) is used. 
Guidelines Diagnosis-specific evidence-based drug 
recommendations developed by professionals. 
MDRD formula Estimated glomerular filtration rate (GFR)= 
32788 x SCr (in micromol/l)-1,154 x age (in year)-0,203 x constant
Constant: 1 for white men, 0.742 for women and 
1.21 for Africans; Absolute GFR = Estimated GFR x body 
surface/1.73m2 Body surface = 0,20247 x height (m)0,725 x weight 
0,425 (6).
Medication Error Any preventable event that may cause or lead to 
inappropriate medication use or patient harm while 
medication is in the control of the health care 
professionals, patient or consumer (7). 
M-DRP DRPs may be counted in different ways. Medication-
DRPs (M-DRP) are all countable DRPs connected to a 
drug.
P-DRP  DRPs may be counted in different ways. Patient-DRPs 
(P-DRP) are clinical DRPs as perceived by the patient.  
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Pharmacist advice  Any proposal made by a pharmacist for intervention with 
the intent of evaluating or changing the patient’s drug 
therapy. Proposals relating to drug distribution, for 
example changing to a chosen generic brand, are not 
included in the definition. 
Polypharmacy The use of five or more different drugs (i.e. substances) 
concomitantly.
Rational drug use Patients receive medication appropriate to their medical 
needs, in doses meeting their own individual 
requirements for an adequate period of time and at the 
lowest cost to them and the community (8).
Renal risk drugs Drugs with recommendations for precautions in patients 
with reduced renal function. 
Renoprotective drugs Renal risk drugs that also have the property of protecting 
renal function.
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1 Introduction 
In the case of most diseases drug therapy will enhance health-related quality of life. However, 
inappropriate use of drugs may be harmful and could evoke new adverse symptoms. This has 
been known for centuries but, it was first when the reports of aplastic anaemia following 
treatment with chloramphenicol (9) and of birth defects after use of thalidomide (10) that the 
interest in drug-related problems (DRPs) increased dramatically. Since then, research in this 
field has been intensified, as has the development of more effective and targeted drugs, and 
the pharmaceutical industry has grown into one of the most important industries in the world. 
A paradoxical consequence is that drug therapy has gradually become more complex, thus 
making it increasingly challenging to prescribe drugs appropriately.  
1.1 To set the scene 
The headline in Pharmacy Today, 2001 “Drug-related problems: Once a $ 76.6 Billion 
headache, now a $ 177.4 Billion migraine” (11) not only underlines the societal consequences 
in terms of costs but also illustrates the chronic impact of DRPs on morbidity and mortality 
(12). DRPs are of major concern in view of their physical, psychological and economic 
burden to the patients and to society as a whole (13;14). Thus, optimising drug therapy – by 
preventing drug-related problems – may influence the health costs, potentially save lives and 
enhance patients’ quality of life (15-17).
Previous studies have mainly addressed DRPs as a cause of hospitalisation (18-25). 
However, DRPs that arise in the hospital setting – under treatment – have rarely been 
described.
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Several administrative initiatives concerning drug quality have been implemented with 
the aim of achieving rational prescribing in hospitals. However, tools like guidelines, printed 
educational material, drug surveillance, audits on drug handling and retrospective feedback to 
prescribers have been reported to have only limited effects (26-28). Moreover, the fact that 
daily life in a hospital, characterised by high patient turnover, lack of time, high speed and 
unplanned events – in many ways a chaotic situation – gives limited room to evaluate existing 
long-term drug treatment. In addition, when treatment with a new drug is started it is difficult, 
owing to the short hospital stay, to optimise the dosage. Also, since steady state often has not 
been reached, it is hard to evaluate the long-term effect and the outcome of possible 
interactions of the new drug with already established drug regimens. This makes it necessary 
to heighten the focus on drug use in hospitals. Preferably, an interdisciplinary approach 
should be put in place to ensure decisions that result in an optimal and rational drug therapy 
for the individual patient, which would reduce the frequency of avoidable drug-related 
problems and benefit society as a whole. 
1.2 What are drug-related problems (DRPs)? 
Adverse drug reactions (ADRs) have been the problems most frequently investigated. 
However, the practical focus in the field of rational pharmacotherapy is much broader than 
just dealing with ADRs. In the long run, other DRPs, such as drug use without an indication, 
improper drug selection, improper dosages, absence of necessary drugs, may be as important 
as ADRs. 
This illustrates the need for a broad approach to the issue of DRPs. By identifying all 
types of problems, also potential DRPs, precautions may be taken to prevent these from 
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becoming overt clinical problems. Furthermore, a broad definition of what constitutes a DRP 
could provide a basis for understanding the whole spectrum of these problems.  
1.3 How may DRPs be identified? 
DRPs have often been addressed by studying large databases (29-31). However, the clinical 
approach – bedside evaluation – increases the likelihood of identifying true DRPs, whereas 
database studies may find “artificial” DRPs, e.g. they may identify as inappropriate a drug 
that in fact is appropriate for the patient in question.
Identification of DRPs demands tools. Explicit criteria such as guidelines and lists of 
drugs with rules of caution are important in this respect but have been somewhat controversial 
because they do not identify all cases of potentially inappropriate prescribing (32-34). Implicit 
review is necessary in the clinical evaluation of individual therapy. On the other hand this 
method, if used alone, could introduce biases connected to the reviewer (e.g. opinions and 
knowledge) that are difficult to identify.
In this study we decided to undertake an implicit review by investigating how DRPs 
were dealt with by multidisciplinary hospitals teams with a clinical pharmacist on board. We 
also decided to use two explicit National lists prepared by specialists in the field, one being 
the recommendations for drug management in patients with reduced renal function and the 
other the list of drug interactions (DDIs).  
1.4 Clinical pharmacists 
Clinical pharmacy is defined as a health speciality, which describes the activities and services 
of the clinical pharmacist to develop and promote the rational and appropriate use of 
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medicinal products and devices (35). Within this definition we find different categories of 
practice ranging from patient education to pharmacokinetic services to participation in 
rounding teams, the last being sometimes described as collaborative drug therapy. Clinical 
pharmacists can play a vital role by addressing the whole range of drug therapy in hospitals 
and, in general, the clinical pharmacy services have been reported to improve patient care by 
reducing inappropriate prescribing (36;37), improve disease management (38;39), diminish 
adverse drug events (40), reduce length of stay, ADRs and mortality (41) and give economic 
benefit (42). More specifically, involving the clinical pharmacy service in collaborative drug 
therapy, that is to say, direct and prospective cooperation between physicians and pharmacists 
on an individual patient’s drug therapy, has been increasingly acknowledged. This 
collaborative process is designed to optimise the patient’s drug therapy and health-related 
quality of life. This type of clinical pharmacy service (rounding team) has been shown to 
improve clinical outcome (43) and reduce adverse drug events in hospitals (44;45). The 
collaboration between pharmacists and physicians has been welcomed by the World Medical 
Association who stated (1999) “physicians and pharmacists have complementary and 
supportive responsibilities in achieving the goal of providing optimal medicinal therapy. This 
requires communication, respect, trust and mutual recognition of each other's professional 
competence” (46). 
Clinical pharmacy services have evolved differently in the various countries, 
influenced by differences in clinical settings, national therapeutic traditions, culture and the 
structure of the health care systems. In Norway, clinical pharmacists in hospitals have taken a 
proactive approach, cooperating directly with physicians and other health professionals in 
multidisciplinary rounding teams (collaborative drug therapy) and are also in direct contact 
with patients. In studies evaluating the pharmacist’s contribution, exact details about the type 
of clinical service are sometimes lacking. Thus, the impact of the pharmacy service is 
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sometimes difficult to assess, since the outcome is dependent on which pharmacist approach 
has been applied. In this study we have applied the current model used in Norwegian 
hospitals, implying that our results will reflect a multidisciplinary proactive approach. 
1.5 Drugs used in patients with renal impairment 
Many patients admitted to hospital have reduced renal function (47-49). However, the 
spectrum of chronic kidney disease extends from slight kidney impairment to severe renal 
damage. In most patients with mild to moderate renal impairment the reduced function may 
not have been diagnosed and these patients are managed in general practice and in general 
hospitals.
Many drugs and their metabolites are eliminated through the kidney. Inappropriate use 
of drugs in patients with renal impairment may cause harm, which makes the handling of 
these patients particularly challenging. Guidance on drug management in patients with 
reduced renal function has therefore been considered to be important, and explicit lists with 
recommendations are available in most countries (50;51). These lists have been developed by 
specialists in the field. They give general recommendations, are adapted to the national drug 
market and are updated routinely. These guidelines are of little value, however, if a 
deteriorating renal function is not acknowledged. Furthermore, we do not know to what extent 
these lists are used in clinical practice. 
1.6 Drug interactions 
The impact of drug interactions (DDIs) has been known for a long time. However, it is only 
during the recent decades that crucial mechanisms causing interactions have been delineated 
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and fully understood. This new knowledge has escalated the recognition of a huge number of 
drug interactions, making it almost impossible for the individual prescriber to keep updated 
and to remember all potentially hazardous drug combinations. Explicit lists of DDIs 
developed and updated by specialists in the field are available in most countries (50;52). 
Moreover, sophisticated computer programmes based on the lists are available for screening 
of the patients’ medication profiles. However, screening takes time and, furthermore, provides 
only a rough estimate, since an identified DDI might be of minor clinical importance in one 
patient but extremely serious in another. Most clinicians agree that it is important to be aware 
of problematic DDIs associated with a patient’s drug regime, but it has not been settled which 
method is most efficient for the identification of clinically important DDIs. 
21
2 Aims of the study  
The purpose of this study was to investigate the occurrence and management of drug-related 
problems (DRPs) in a hospital setting. The specific aims were as follows: 
 to identify and describe the magnitude and types of DRPs in hospitalised patients 
(Paper I) 
 to identify risk factors for DRPs and the drugs that most frequently cause DRPs
(Paper I) 
 to investigate the extent to which pharmacists contribute to the therapeutic hospital 
team in terms of evaluating the drug regimens of individual patients (Paper II) 
 to investigate the pharmacists’ priorities on drug issues, their therapeutic advice and 
how this advice is dealt with (Paper II) 
 to investigate the appropriateness of drug use and the occurrence of DRPs in 
hospitalised patients with mild to severe renal impairment (Paper III)  
 to evaluate and compare two methods – computerised screening and clinical bedside 
recording – as regards the capability to identify drug interactions in hospitalised 
patients (Paper IV) 
22
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3 Materials and methods 
3.1 Study design 
The four papers included in this thesis are based on a multicentre investigation. The study was 
designed primarily to investigate the occurrence of drug-related problems (DRPs) in general 
hospital populations, but also to examine interventions in relation to the observed DRPs. Thus 
the study can be described as both a clinical study and a prospective observational cohort 
study.
3.2 Study population  
The clinical data were collected at five hospitals during the period May to December 2002. 
Four of the hospitals are located in Oslo, the capital of Norway and its largest city 
(approximately 550 000 inhabitants), and one in Bergen, the second largest city in Norway 
(approximately 235 000 inhabitants). Wards that had specifically appointed clinical 
pharmacists to rounding teams were selected for participation. The pharmacists (i.e. the data 
collectors) visited the wards three to five days per week (one ward two days a week), 
weekends not included. Since most of the patients admitted during a weekend were 
hospitalised for a longer time than just the weekend, nearly all the hospitalised patients were 
captured and recruited to the study.
Patients admitted to six wards for internal medicine – represented by cardiac, 
respiratory and geriatric wards – and two wards for rheumatology were enrolled in the study 
(Figure 3.1 and 3.2). Emergency departments were not included. All of the internal medicine 
Bergen 
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wards were acute general wards with patients admitted from local general practices. The 
rheumatology departments had regional referral. Patients were included in the study 
consecutively and followed up prospectively during their hospital stay. Patients who were 
readmitted during the study period were included on first admission only.  
Figure 3.1 Patient enrolment to the various wards at the various hospitals. Hospitals 
included were: Haukeland University hospital (H), Ullevål University hospital (U), 
Lovisenberg Diakonale hospital (L) Diakonhjemmets hospital (D), Aker University hospital 
(A).
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Figure 3.2 Patient distribution by age and gender.
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3.3 Data collection  
The patients were approached individually. Experienced clinical pharmacists collected data 
from medical charts, medical records, physicians’ ward rounds and the multidisciplinary 
meetings where each patient was discussed with regard to diagnosis, management and follow-
up (Figure 3.3). Participants at the morning meeting were physicians, nurses and clinical 
pharmacists, and occasionally physiotherapists and other health professionals. Information 
was also collected, if possible, by talking with the patients. A standard data recording form 
was used (Annex I). The form had been designed, tested and found applicable to the 
participating departments.  
The following data were recorded for each patient: age, gender, drugs used at 
admission, drugs started during the hospital stay, relevant medical history, reason for 
hospitalisation and results of routine laboratory tests. Some specific factors that are assumed 
to increase the risk of DRPs arising were recorded. The selected factors were those most often 
mentioned in the literature as risk factors. These, which are a mixture of pharmacological, 
clinical and patient-related factors, here called clinical/pharmacological risk factors, were the 
following: polypharmacy (defined as ≥5 drugs at admission), reduced renal function 
(glomerular filtration rate (GFR) below 50 ml/min or serum creatinine (SCr) above normal 
range), reduced liver function (aspartate aminotransferase (AST) or alanine aminotransferase 
(ALT) three times above normal values), confirmed diabetes mellitus, cardiac failure, history 
of allergy or adverse reactions to drugs, assumed non-compliance (based on information 
gathered from the patient, medical record or health care staff), use of drugs with a narrow 
therapeutic index (defined by an explicit list in the data collection form), and other factors that 
could affect taking the prescribed drugs, including alcohol misuse and swallowing problems 
that might hamper intake of the drugs in question. 
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Figure 3.3 Flow chart for the prospective multicentre study.
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Oslo Group of Clinical Pharmacists, LOOK) in an attempt to standardise the classification 
procedure. The clinical pharmacists participating in this study as data collectors were part of 
that network. Consequently, the participating pharmacists had a common understanding of the 
classification used in the study.
The pharmacist assessed whether the patient had DRPs by using explicit criteria listed 
in national (50) and local guidelines and Felleskatalogen (The Norwegian Drug Catalogue) 
(52). The guidelines include separate lists of drug interactions as well as separate lists of 
drugs that are inappropriate to use in patients with renal or liver failure. DRPs that had been 
identified and handled appropriately were no longer a problem and consequently were not 
recorded as such. Some DRPs (a minor proportion) were identified by the pharmacist, and 
although not discussed or acted upon were nevertheless recorded as DRPs. Most DRPs were 
evaluated by the multidisciplinary team which was chaired by the physician, who made the 
final decision about acknowledgement of DRPs and what action should be taken. 
One specific drug may introduce more than one DRP, some of them being 
interdependent. For example, a given drug may have caused an interaction, leading to too 
high dosage and a need to monitor the effect of the drug by means of laboratory tests. Thus, 
three DRPs could be related to the drug, but the patient might perceive only one DRP – the 
actual drug itself. Therefore the frequency of DRPs per patient was specified both as the 
number of Medication-DRPs (M-DRP), a term primarily suited for scientific purposes, and as 
the number of Patient-related DRPs (P-DRP). Consequently, the number of M-DRPs is higher 
than the number of P-DRPs. In Paper I both ways of classifying DRPs were applied. In Papers 
II, III and IV, the first approach was used and the reported frequencies of DRPs were based 
on the counting of all recorded DRPs.
We also introduced a “drug risk ratio” for each drug, which was the number of DRPs 
in relation to the number of times the medication was used. 
28
Table 3.1 Classification of drug-related problems (DRPs). 
• Need for additional drug  
• Unnecessary drug
• Non-optimal drug, incl. non-optimal drug formulation  
• Non-optimal dosing, incl. non-optimal dosing schedule  
• No further need for the drug
• Drug interactions
• Need for monitoring  
• Adverse reaction (experienced) 
• Medical chart error
• Patient education required
• Specific information/discussion of therapy  
• Patient adherence problems  
• Others
3.5 Pharmacist interventions (i.e. pharmacist proposals for therapy interventions) 
The pharmacists participated in the meetings of the multidisciplinary therapeutic team. In 
these team meetings the identified DRPs were brought up for discussion and evaluation 
(Figure 3.4). The pharmacist’s advice was recorded, along with the physician’s decisions 
regarding the patient’s drug therapy. Pharmacist advice was defined as: “any pharmacist 
proposal for intervention made with the intent to evaluate or change the patient drug 
therapy”. Proposals concerning drug dispensing and distribution, aimed at assuring 
compliance with drug therapy lists, were not included.
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Responses to the pharmacist’s advice were recorded in three categories:
1. “Yes” - immediate acceptance by the physician and subsequent action.
2. “No” - the physician did not approve the pharmacist’s proposal and no action was 
taken.
3. “Accepted” - agreed by the physician, who noted the proposal, but no immediate 
action was taken.
Some DRPs connected with proper drug handling were not brought up for discussion 
with the physicians, but were discussed directly with the nurses handling the drugs at the 
hospital or with the patients themselves. These DRPs were recorded separately as pharmacist 
advice to nurse/patient.
Some pharmacist-identified DRPs were not brought up for discussion, either with 
physician, nurse or patient. In such cases the reasons for not discussing an identified DRP 
were noted, and were grouped as follows:
1. “Not given priority” - e.g. DRPs that could not appropriately be solved at the hospital 
or in the specific clinical situation, or that other DRPs were considered by the 
pharmacists to have higher priority.
2. “No longer relevant” - e.g. the DRPs were solved before the team discussions took 
place, or the patient had died or been transferred to another department/hospital.  
3. “Other reasons” - e.g. the DRPs were not given immediate priority at the time, but the 
intention was to discuss them later during the hospital stay.
The patients with DRPs were grouped into three categories: patients all of whose 
DRPs were discussed; patients some of whose DRPs were discussed; patients none of whose 
DRPs was discussed. 
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Figure 3.4 Flow chart showing how pharmacist-identified DRPs were handled.
                       125                      928                 411                     119               
3.6 Grading of renal impairment and renal risk drugs 
The patients were divided into groups according to grade of renal impairment (RI). The 
grading into five stages of RI was made in harmonisation with the definition given by the 
National Kidney Foundation (54) (Table 3.2). This grading is based on the GFR. The Kidney 
Disease Outcomes Quality Initiative (K/DOQI) recommends that GFR be calculated from 
calibrated SCr and estimating equations. Two main methods are recommended: the 
Cockcroft-Gault equation and the Modification of Diet in Renal Disease (MDRD) formula. 
Admitted to hospital 
827 patients 
Identification of 2128 DRPs 
in 672 patients 
Selected for 
review by quality 
team, 373 DRPs 
Morning meeting: 
discussion of 1458 DRPs 
545 DRPs not 
discussed
125 DRPs only 
discussed with patients 
or nurses 
No action taken Yes, action taken, 
DRP resolved
Accepted, but no 
action taken
31
Table 3.2 Renal function classified according to the National Kidney Foundation’s definition 
(54).
stage 1 (normal kidney function) GFR  90 ml/min/1.73m2
stage 2 (mild reduction of GFR) GFR 60-89 ml/min/1.73m2
stage 3 (moderate reduction of GFR) GFR 30-59 ml/min/1.73m2
stage 4 (severe reduction of GFR) GFR 15-29 ml/min/1.73m2
stage 5 (kidney failure) GFR  15 ml/min/1.73m2
Until recently, the Cockroft-Gault equation has been the reigning method of 
calculating GFR in Norway and the MDRD method was not used widely in clinical practice 
until 2006 (55). The Cockcroft-Gault equation is considered to be a good bedside estimate of 
renal status when considering drug therapy. Therefore, together with the usual pragmatic 
clinical evaluation of the level of SCr as a marker of renal function, the Cockcroft-Gault 
equation was used prospectively during the study period to find out into which category of 
renal function the patients should be registered. Patients with reduced renal function were 
regarded to be at risk for occurrence of DRPs (see 3.3 data collection, 
clinical/pharmacological risk factors).  
The Cockcroft-Gault method calculates creatinine clearance based on age, gender, SCr 
and patient’s weight. Information about weight was not available for all patients. The MDRD 
formula is simpler, since it requires only information on SCr, gender and age. Retrospectively 
we applied this simpler formula to calculate the GFR for nearly all the patients included in the 
study (808 of 827 patients). SCr was not obtained for 19 of the patients. We used the National 
Kidney Foundation’s GFR calculator to calculate GFR by means of the MDRD formula (56). 
Patients in stages 1 and 2 (normal or mild reduction of renal function) were considered to 
have adequate kidney function in relation to drug therapy, while patients in stages 3, 4 and 5 
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were considered to have impaired renal function and to be in need of special attention as 
regards drug therapy. 
Precautions are recommended when certain drugs and classes of drugs that are 
eliminated through renal excretion are to be used in patients with RI. These drugs were 
designated renal risk drugs. We used the lists and recommendations in the Norwegian 
National Therapy Guidelines (50) and similar lists in the British National Formulary (51) to 
assign drugs to the renal risk drug group. Further, we classified renal risk drugs into three 
main categories: drugs for which dose adjustments are recommended; drugs to be used with 
caution; drugs to be avoided in patients with RI (Table 3.3). Some renal risk drugs were 
classified into more than one category, for example, in the cases of the benzodiazepines, 
caution is advised owing to cerebral sensitivity in patients with RI, and it is recommended that 
in patients with this condition the therapy should be started in small doses, i.e. the dose should 
be adjusted.
Some drugs included in the lists of renal risk drugs may also have renoprotective 
properties. These – with recommendations for handling in the event of RI – are: ACE 
inhibitors (caution – reduce dose); angiotensin II antagonists (caution – reduce dose); calcium 
channel blockers (caution when initiating therapy); some statins (simvastatin: dose above 10 
mg to be used with caution, pravastatin: start with small doses, fluvastatin: avoid in severe 
RI). These drugs were included in the total number of renal risk drugs, but were also depicted 
separately as renoprotective drugs. 
In order to better describe the risk to the individual patient we introduced the 
“proportion of drugs at risk”, i.e. the proportion of renal risk drugs in relation to the total 
number of drugs used.   
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Table 3.3 Categorisation of renal risk drugs and drug groups with special recommendations 
for use in patients with renal impairment (RI).
 Drug groups (ATC) with general cautions rules in RI 
Dose adjustment 
 Caution, reduce dose in mild to 
moderate RI 
Insulins (A10A), drugs for acid-related disorders (A02),
quinolones (J01M), NSAIDs (M01A)
 Reduce dose in severe RI Penicillins (J01C), cephalosporins (J01D)
 Start with small doses Calcium channel blockers (C08), antipsychotics (N05A),
anxiolytics (N05B), hypnotics and sedatives (N05C)
Caution
 Caution Betablocking agents (C07A), ACE/angiotensin II antagonists 
(C09)
 Caution, monitor serum conc.  Aminoglycosides (J01G)
 Increased bleeding tendency Antithrombotic agents (B01A)
 Increased cerebral sensitivity Opioids (N02A), antipsychotics (N05A), anxiolytics (N05B),
hypnotics and sedatives (N05C)
Avoid
 Avoid in mild to moderate RI Thiazides (C03A), potassium-sparing agents (C03D, C03E)
 Avoid in severe RI Antithrombotic agents (B01A), bisphosphonates (M05B)
3.7 Drug interactions (DDIs) 
Stockley uses a broad definition of interactions: An interaction is defined to occur when the 
effects of one drug are changed by the presence of another drug, food, drink or some 
environmental chemical agent (4). In computerised screening programmes for interactions, a 
more limited definition is applied, with the focus on drug-drug interactions.
The drug regimens were screened using of the internet-based Norwegian Drug 
Information Database (DRUID) (57). This program includes a generally accepted grading of 
drug interactions in relation to clinical significance (58). 
In this programme DDIs are divided into four classes:
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• Class A: Drug combination should always be avoided. Risk always 
outweighs benefit.  
• Class B: Drug combination should usually be avoided. The actual 
combination should only be used when special precautions are taken. Use of 
other drug combinations should be considered, or if the combination is 
chosen, then the drug use should be monitored closely. 
• Class C: The drugs can be combined, but action should be taken as necessary 
to reduce risk, for example changing timing of drug dose or the routes of 
administration.
• Class D: No action needed. Risk of adverse outcome appears to be small. 
In addition to recording DDIs of different grades we noted whether the DDIs in 
classes A, B and C were new ones, that is to say, were connected to drug therapy started after 
admission to hospitals. Heightened awareness is required for new DDIs compared with 
interactions that have existed for a long time in the patient’s drug regimen. We used the term 
DDInew when the DDI was initiated by the addition of a new drug that could interact with a 
drug used at admission or with another new drug introduced at hospital.
In the bedside approach, only DDIs regarded as import and a clinical problem for the 
patient concerned were recorded as DRPs, regardless of type of interaction, i.e. type A, B, C 
or D. This implies, for example, that a type A DDI was only recorded as a DRP when the drug 
in question was assessed as being inappropriate for a specific patient. In the bedside approach 
other substances that could possibly cause interactions when used or taken in by the patient, 
e.g. tobacco, grapefruit juice and ethanol, were registered and assessed. We did not 
specifically ask for information on such substances, but if this information was contained in 
the medical record or communicated by the patients, possible interactions were assessed and, 
if considered to be a problem, included in the count of drug interactions (DDIs). 
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3.8 Quality assessment 
The multidisciplinary meeting acted as a first body for quality assessment of the DRPs. In 
addition, an independent quality assessment team was appointed, consisting of a professor in 
pharmacotherapeutics, who is also a specialist in internal medicine, and two specialists in 
hospital pharmacy with long experience as clinical pharmacists. The DRPs of every sixth 
patient were randomly chosen for this quality assessment (Figure 3.3). The team 
retrospectively assessed the clinical significance of the registered DRPs. Assignment of DRPs 
to categories of clinical significance was performed by the team (consensus method) after all 
three members had made their own evaluation. If the judgements differed, the case was 
discussed and consensus was reached.  
The clinical significance was assigned to 4 categories: extremely important, major, moderate 
or minor: 
1. Extremely important: DRPs requiring intervention in order to save life or prevent 
severe or irreversible detrimental effects. For example the need to discontinue oral 
hormonal contraceptives in a smoker admitted with possible pulmonary emboli. 
2. Major clinical significance: DRPs requiring intervention in order to prevent a major to 
moderate or reversible detrimental effect or lack of accepted evidence-based therapy, 
for example the need for ACE inhibitors in patients suffering heart failure.
3. Moderate clinical significance: DRPs requiring intervention leading to moderate 
benefit for the patient, for example early switch to oral antibiotics.
4. Minor clinical significance: DRPs of little clinical importance for the patient, such as 
non-important time adjustments for dosages. 
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3.9 Ethics and approval 
The study protocol and consent procedure was approved by the Regional Committee for 
Medical Research Ethics and the Norwegian Social Science Data Services (NSD). 
Data collection was approved by hospital directors, heads (chief physicians) of the 
involved departments and pharmacy directors. Data on each patient was collected using a 
standardised form and was coded by numbers. The code lists were kept at the hospitals. 
3.10 Data handling and statistical analysis 
The collected information was entered into a database constructed for the study. Drugs were 
coded according to the Anatomical Therapeutic Chemical (ATC) classification system (59).
The data was analysed in SPSS 11.0 and 12.0 for Windows. Descriptive statistics are 
shown as means and frequencies with standard deviations or standard errors. P-values less 
than 0.05 (p < 0.05) were accepted as statistically significant.  
In Paper I, a log-transformation was applied to ensure that the dependent variable 
followed an approximately normal distribution. The log-linear regression was carried out with 
the number of P-DRPs as the dependent variable and possible risk factors as independent 
variables, to explore the relationship between the occurrence of DRPs and different patient 
characteristics. In addition, the relationship between several of the most common DRPs and 
the risk factors was studied by means of a logistic regression.
In Paper II, Pearsons chi-square test was performed to examine associations between 
patient groups, gender and response. ANOVA tests were used to study differences between 
groups for the continuous variables of age, drugs used at admission, number of 
clinical/pharmacological risk factors and number of DRPs.  
37
In Paper III, differences between patients with renal impairment, stages 3, 4 and 5 and 
patients with adequate function, stages 1 and 2, were tested by independent samples T-tests 
for continuous variables, and by chi-square tests for categorical variables.  For each category 
of DRP, the Kruskal-Wallis test was used to test for differences in the mean number of DRPs 
per patient among patients with different stages of renal impairment, since these data showed 
strong deviations from the normal distribution. 
In Paper IV, differences between patient groups with and without DDIs were tested. 
Independent samples T-tests were used for continuous variables, while chi-square tests were 
used for categorical variables. 
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4 Synopsis of the studies 
4.1 Paper I:  
Blix HS, Viktil KK, Reikvam Å, Moger TA, Hjemaas BJ, Pretsch P, Vraalsen TF, Walseth EK. 
The majority of hospitalised patients have drug-related problems: results from a 
prospective study in general hospitals. Eur J Clin Pharmacol 2004;60(9):651-8. 
Objective: To describe the frequency and types of drug-related problems (DRPs) in 
hospitalised patients and to identify risk factors for DRPs and drugs most frequently causing 
them.  
Methods: From May to December 2002, 827 patients from 6 internal medicine and 2 
rheumatology departments in 5 hospitals in Norway were included in this study. We recorded 
demographic data, drugs used, relevant medical history, laboratory data and 
clinical/pharmacological risk factors i.e. reduced renal function, reduced liver function, heart 
failure, diabetes, compliance problems, drugs with a narrow therapeutic index and drug 
allergy. DRPs were documented after reviewing medical records and participation in 
multidisciplinary team discussions. An independent quality assessment team retrospectively 
assessed the DRPs in a randomly selected number of the study population. 
Results: 81% of the patients had DRPs and an average of 2.1 clinically relevant DRPs was 
recorded per patient. The DRPs most frequently recorded were dose-related problems (35.1% 
of the patients) followed by need for laboratory tests (21.6%), non-optimal drugs (21.4%), 
need for additional drugs (19.7%), unnecessary drugs (16.7%) and medical chart errors 
(16.3%). The patients used an average of 4.6 drugs at admission. A multivariate analysis 
showed that the number of drugs at admission and the number of clinical/pharmacological 
risk factors were both independent risk factors for the occurrence of DRPs, whereas age and 
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gender were not. The drugs most frequently causing a DRP were warfarin, digitoxin and 
prednisolone, with calculated risk ratios 0.48, 0.42 and 0.26, respectively. The drug groups 
causing most DRPs were B01A-antithrombotic agents, M01A-NSAIDs, N02A-opioids and 
C09A-ACE inhibitors with risk ratios of 0.22, 0.49, 0.21 and 0.35 respectively. 
Conclusions: The majority of hospitalised patients in our study had drug-related problems. 
The number of drugs used, and the number of clinical/pharmacological risk factors, 
significantly and independently influenced the risk for DRPs. Procedures for identification of, 
and intervention on actual and potential DRPs, along with awareness of drugs carrying a high 
risk for DRPs, are important elements of drug therapy and may contribute to diminishing drug 
related morbidity and mortality.  
4.2 Paper II:  
Blix HS, Viktil KK, Moger TA, Reikvam Å.  
Characteristics of drug-related problems discussed by hospital pharmacists in 
multidisciplinary teams. Pharm World Sci 2006;28(3):152-8.
Objective: To investigate pharmacist contribution in the therapeutic hospital team by studying 
drug-related problems (DRPs), pharmacist therapy advice and consequences of the advice.
Methods: From May to December 2002, 827 patients in 5 Norwegian hospitals were included 
in the study. Demographic data, drugs used, relevant medical history, laboratory data and 
clinical/pharmacological risk factors were recorded prospectively at the wards.  
Main outcome measure: DRPs, patients characteristics, pharmacist advice to physicians, 
nurses or patients, response to the pharmacist advice, and reasons (stated by the pharmacist) 
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for not discussing an identified DRP, were reported. An independent quality assessment team 
retrospectively assessed the DRPs for a randomly selected number of the study population. 
Results: On average 2.6 DRPs per patient were found. A total of 2128 DRPs were registered 
and of these 1583 (74%) DRPs were brought up for discussion. Physician immediate 
acceptance rates varied from 80% (for extremely important clinically significant DRPs) to 
50% (for DRPs of minor clinical significance). High age, use of many drugs at admission, 
existence of many DRPs and many clinical/pharmacological risk factors for DRPs were 
associated with low immediate acceptance rate. Type of DRP influenced how the DRP was 
discussed; adverse drug reaction (ADR) and unnecessary drug were discussed with physicians 
while e.g. medical chart error and need for patient education were discussed with 
nurses/patients. Reasons for not discussing DRPs in the team were: not given priority (37%), 
no longer relevant (31%) and others (31%). DRPs of minor clinical significance were most 
often excluded from discussion (37%) as opposed to 14% and 22% of those of moderate and 
major clinical significance.  
Conclusions: The majority of patients had one or more DRPs. The problems identified as 
DRPs by the pharmacists were accepted as such by the physicians and to a high degree acted 
upon. Both clinical significance of the DRP and patient characteristics influenced physician 
immediate acceptance rate. Some DRPs could be solved by direct contact with nurses or the 
patients. Awareness of DRPs increases through participation of pharmacists in the 
multidisciplinary therapeutic hospital team. 
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4.3 Paper III:  
Blix HS, Viktil KK, Moger TA, Reikvam A. 
Use of renal risk drugs in hospitalized patients with impaired renal function – an 
underestimated problem? Nephrol Dial Transplant. 2006;21(11):3164-71.
Background: Inappropriate use of drugs in patients with renal impairment (RI) may be 
harmful and have deleterious effects. We aimed to investigate the use of renal risk drugs in 
such patients in general hospitals and to analyse the relationship to demographic factors, risk 
factors and occurrence of drug-related problems (DRPs).  
Methods: Patients admitted to departments of internal medicine and rheumatology in 5 
general hospitals were included. We recorded demographic data, drugs used, drugs described 
to be a risk in RI (renal risk drugs), relevant medical history, laboratory data and 
clinical/pharmacological risk factors. We used levels of glomerular filtration rates (GFR), 
calculated by the Modification of Diet in Renal Disease (MDRD) formula to classify patients 
into five stages of renal function. DRPs were recorded and assessed in multidisciplinary 
hospital team discussions.
Results: Of the 808 included patients: 293 (36%) had normal renal function (stage 1), 314 
(39%) had mild RI (stage 2), 160 (20%) had moderate RI (stage 3), 35 (4%) had severe RI 
(stage 4) and 6 (0.7%) had kidney failure (stage 5). Mean number of drugs used per patient in 
patients with RI (stages 3, 4 and 5) and patients evaluated to have adequate renal function 
relative to drug therapy (stages 1 and 2): on admission 6.2 vs. 4.1; started in hospital 4.3 vs. 
3.9; total number of renal risk drugs 6.1 vs. 4.5. All but six patients with RI stages 3, 4 and 5 
used two or more renal risk drugs. 124 (62%) of the patients with RI stage 3, 4 and 5 had 
DRPs linked to the renal risk drugs, and 26% of the renal risk drugs were associated with 
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DRPs. The most common drug classes associated with DRPs were antibacterials, 
antithrombotic agents, ACE inhibitors, opioids and NSAIDs.
Conclusions: Among patients admitted to general hospitals, a considerable proportion had 
renal impairment. In patients with reduced renal function, renal risk drugs were widely used 
and often in combination. DRPs were frequently associated with the use of renal risk drugs.
4.4 Paper IV:   
Blix HS, Viktil KK, Moger TA, Reikvam A. 
Comparison of two methods for identification of drug interactions: computerised 
screening versus bedside recording. Submitted. 
Objective: To compare two methods for identification of drug interactions (DDIs) - 
computerised screening and prospective bedside recording - with regard to capability of 
identifying DDIs. 
Methods: Patient characteristics were recorded for patients admitted to five hospitals. By 
bedside evaluation drug-related problems, including DDIs, were prospectively recorded by 
pharmacists and evaluated in multidisciplinary teams. A computer screening programme was 
used to identify DDIs retrospectively - dividing DDIs into four classes: A, avoid; B, 
avoid/take precautions; C, take precautions; D, no action needed. 
Main outcome measure: Proportion of patients with DDIs; number and types of DDIs. 
Results: Among 827 patients computer screening found DDIs in 544 patients (66%); 351 had 
DDIs introduced in hospital. The 1513 computer identified DDIs had the following 
distribution: type A, 78; type B, 915; type C, 38; type D, 482. By bedside evaluation, DDIs 
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were found in 73 patients (9%), with a total of 99 DDIs. The proportions of computer 
recorded DDIs which were also identified bedside were: 5%, 8%, 8%, 2% of DDIs type A, B, 
C, D, respectively. In 10 patients, DDIs not registered by computer screening were identified 
bedside. By computer screening, the drugs most frequently involved in DDIs were 
acetylsalicylic acid, warfarin, furosemide and digitoxin and by bedside evaluation warfarin, 
simvastatin, theophylline and carbamazepine.  
Conclusions: Despite active prospective bedside search for DDIs, this approach identified 
only a small proportion - less than one in ten - of the DDIs recorded by computer screening. 
This also pertained to DDIs reported by the computer screening to be hazardous. Computer 
screening overestimates considerably when the objective is to identify clinically relevant 
DDIs.
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5 General discussion 
The results of the separate papers (Papers I-IV) constituting this thesis have been considered 
in the discussion section of each of the papers. Thus only the most important findings are 
discussed here. 
5.1 Main results 
 The majority of hospitalised patients had DRPs 
 In logistic regression analysis both the number of drugs at admission and number of 
clinical/pharmacological risk factors were independent risk factors for occurrence of 
DRPs, but age and gender were not 
 The observed drug risk ratios for the various drugs exhibited a wide range of variation
 DRPs identified by pharmacists were largely accepted as such by the physicians and to 
a high degree acted upon 
 The physicians’ rate of immediate acceptance was influenced by the clinical 
significance of the DRP and by special patient characteristics  
 The clinical significance of the DRP influenced whether or not it would be discussed 
by the multidisciplinary team 
 Some DRPs could be solved directly through contact with nurses or the patients 
themselves 
 A sizeable proportion of hospitalised patients had renal impairment; renal risk drugs 
were widely used in these patients and often in combination 
 DRPs were frequently associated with the use of renal risk drugs 
 A prospective bedside approach identified only a small proportion – less than one in 
ten – of the DDIs reported by computer screening  
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 Computer screening highly overestimates DDIs and is of limited value for assessing 
DDIs
5.2 Discussion of main findings 
5.2.1 DRPs (Aim I) 
Our finding of a high frequency of DRPs at clinical departments – over four-fifths of the 
patients had one or more DRPs – highlights the benefit of establishing a multidisciplinary 
team with the task of making a holistic assessment of the drug therapy. Patients admitted to 
hospital need special attention as regards drug therapy. Often they are severely ill and will be 
prescribed many potent drugs during the acute phase. Exacerbation of the disease or 
contraction of infection may temporarily influence drug pharmacokinetics and pharmacology. 
Such situations present a huge challenge to hospital physicians, who often need to take rapid 
decisions that might also influence the effects of the patient’s stable long-term drug regimens. 
In the medical hierarchy the hospitals are specialised in acute care, and the segregation into 
departments with high clinical expertise on specific diseases will provide good and focused 
treatment for the conditions that caused admission to hospital. However, the specialisation 
may imply less focus and expertise as regards the treatment of the patients’ concomitant 
disorders.
The large amount of DRPs identified in our study reflects the chosen definition of 
DRPs, which includes potential as well as actual DRPs. It has been debated whether a 
potential DRP that does not necessarily become a real concrete problem, should be included 
in the term DRP (60-62). We would argue that a potential problem should be regarded as a 
DRP because – if not dealt with properly – it will frequently cause negative outcomes. Many 
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studies have shown that a large proportion of DRPs causing hospital admissions are 
preventable (15;16;18;22;63-66), which emphasises the need to take potential DRPs into 
consideration when evaluating drug regimens. The definition of drug-related problems 
(DRPs) has been widely discussed but, as yet, international agreement has not been achieved 
(53;60-62).
The area “DRPs” overlaps with the area of “Medical Errors”. Both these areas are of 
significant concern (67). The extended concept of Medical Errors has been awarded massive 
attention in the United States since 1999, when the Institute of Medicine published their 
report: “To Err is Human: Building a safer Health system” (7). This issue has received 
attention in Norway as well, and strategies have been developed to reduce the problem of 
errors in medication (68). However, these strategies refer mainly to administrative 
management and quality assurance. A DRP as such is not always a consequence of error, it 
may rather be a consequence of changes in pharmacology, pharmacokinetics, severity of the 
disease, or adjacent events that are difficult to foresee.  
In the literature, considerable differences in DRP frequency have been reported 
(19;69-74). The lack of standardised methods for identifying prevalence of DRPs restricts the 
possibility to compare therapeutic traditions across settings, hospitals and countries. Much of 
this controversy can be explained by differences in the definition and operationalisation of the 
term. One element of the discussion concerns whether the definition should include potential 
DRPs. It has also been debated what categories of DRPs should be included. Clusters of 
problems have been called “drug-related problems” (53), “medicine-related problems” 
(75;76), “medication-related problems” (71;77), “inappropriate drugs” (78) “negative clinical 
outcome” (62), “suboptimal prescribing” (79) and so on. To be able to make relevant 
comparisons there has to be methodological similarity. At the present time different 
operational classifications of DRPs are used (5;53;60;80;81). The classifications are not 
48
consistent and the variation can be confusing. International agreement on the definition of the 
term as well as recommendations for easy, practical and reliable operationalisation of the 
term, is urgently needed. Only after this has been achieved can we get a clear picture of what 
we actually are discussing. 
The area of DRPs is important for society in terms of health costs and quality of care. 
The lack of standardised operational classification tools makes it difficult, not only for 
researchers in the field, but also for quality assurance that could have made use of a unified 
DRP classification system for clinical documentation, as well as for comparisons, for 
example, between different practices, wards or hospitals. Tools aimed at improving the 
quality of prescribing, such as audits and retrospective feedback on practice, have been 
frequently utilised in quality assurance (82-84). These tools have been shown to have some 
effectiveness in improving professional practice (26). For the individual clinician, feedback on 
his/her own practice is often more educational and encouraging than for example comparisons 
across borders, owing to differences in therapeutic traditions, health care systems and health 
culture. Quantification of DRPs might possibly serve as a quality indicator for drug use and 
accordingly be used in quality procedures, in hospitals, general practice and pharmacies.  
International agreement on the DRP notion seems to take time, so in the meantime a 
national standard would be advantageous. In Norway, the present study is the first to look into 
the extended area of DRPs in hospitals. Together with a research group in Bergen, who have 
carried out a study on DRPs in nursing homes and used a different tool of classification (85), 
we have recently developed a common tool for identification of DRPs. This tool is intended to 
be used by professionals in the field and applied in general practice, pharmacies, nursing 
homes and hospitals. It can be used to identify DRPs within the patients’ drug regimens and 
in summaries depicting the practitioners’ work on DRPs, or it can be used in research. The 
system is simple in form, but can easily be transformed into a more complicated instrument 
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for research (Appendix II). However, if this tool is to be used as an indicator of quality, it is 
necessary to undertake a validation procedure and to test out whether it can indeed be used as 
such (86;87). 
5.2.2 Risk factors for DRPs (Aim II) 
The identification of risk factors for DRPs may be helpful in finding patients at risk. These 
patients can then be singled out for special attention, with the hope of avoiding overt DRPs. 
We found that an increased number of clinical/pharmacological risk factors significantly 
heightened the risk of occurrence of DRPs. The clinical/pharmacological risk factors were 
identified from a predetermined list of acknowledged factors described in the literature. It 
may be difficult to use the cluster of clinical/pharmacological risk factors in connection with 
individual patients, since this composition of factors is heterogeneous and relates to diseases, 
drugs and behaviour. In clinical practice it is often easier to deal with one risk factor, for 
example renal impairment, at a time. However, in reports and surveys in the field of health 
administration, it may be practical to use the mean number of clinical/pharmacological risk 
factors per patient in a particular department as an indicator of the risk of DRPs. This 
information can be used to identify high-risk departments in need of clinical pharmacist 
services.
We found a strong relationship between an increasing number of drugs used and 
increasing number of DRPs, which is not surprising. However, this risk factor for DRPs is 
difficult to utilise in clinical practice. This issue was highlighted by the results from another 
study in this project (88) where it was concluded that setting a strict cut-off and defining 
polypharmacy as the use of more than five drugs, for example, offers no advantage.  
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It is important to identify drugs that are prone to create problems. We introduced the 
drug risk ratio to quantify this tendency among the various drugs. A more comprehensive 
drug list than the one presented in Paper I is shown in Figure 5.1. It is necessary to be aware 
of the drugs with the highest drug risk ratio since these are those that most frequently expose 
the patient to risk when taking these drugs. On the other hand, it is also necessary to be aware 
of frequently used drugs with a lower drug risk ratio. Because these drugs are commonly used 
health workers may consider them safe. However, a drug risk ratio of 0.26, which was the 
ratio found for prednisolone, means that, in fact, a DRP may occur in one fourth of the times 
the drug is used.
Figure 5.1 Times used and drug risk ratio for the 12 most utilised drugs (right) and for the 12 
drugs with highest drug risk ratio (left).
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5.2.3 Clinical pharmacists (Aim III)  
Handling of identified DRPs is not a straightforward procedure. In a British study, 45% of the 
participating GPs felt they did not have the adequate skills to solve medicine-related problems 
(89). DRPs are probably handled most successfully by multidisciplinary teams. In the end, 
permanent drug changes should be implemented in collaboration and concordance with the 
patient. This is the ideal situation that probably would give the best results. In the setting of 
acute hospital medicine it is difficult for the patient to achieve adequate understanding of 
complicated therapies. Therefore it is sensible that professional discussions on the optimal 
handling of DRPs – and associated drug reviews – be held within the hospital team, after 
which the therapeutic options can be presented to the patient.
Historically, physicians have been wholly responsible for the patient’s therapeutic 
management. They still make the final decision but nowadays pharmacists are becoming 
increasingly involved in the management of the patients’ drug regimens by providing 
comprehensive medication reviews, educational efforts directed at patients and health 
personnel and by proactive participation in multidisciplinary teams. Clinical pharmacists are 
supposed to possess an in-depth knowledge of medications and also have a fundamental 
understanding of biomedical, pharmaceutical and clinical sciences. The inclusion of clinical 
pharmacists into the hospital health care team has been shown to result in fewer ADRs , fewer 
medication errors, improved drug adherence, better patient knowledge of drugs, reduced 
hospital stay and lower costs (41;90).
In Norway, the first clinical pharmacy services were established as a routine in 1996. 
The services observed in the present study (2002) were provided mainly by pioneers in the 
field. The study was undertaken in departments with established clinical pharmacy practices, 
organised with pharmacists as parts of the multidisciplinary team. The clinical pharmacists 
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had the specific task of searching for DRPs and solutions were found in collaboration with 
other health care workers. We found that most of the identified DRPs were discussed in the 
team, indicating that the pharmacists are active partners in the multidisciplinary discussions. 
This way of handling DRPs is labour intensive, requiring a high work load by clinical 
pharmacists. However, it is probably the most effective approach to the problem, since 
continuous high intensity monitoring ensured that many DRPs that may otherwise have been 
overlooked were discovered. This view is supported by reports from other researchers 
(91;92). The multidisciplinary team approach implies stronger focus on questions of drug 
therapy at the meetings. This appears to be time consuming, but since the questions are often 
the same in other similar cases and the solutions often transferable, the team meetings could 
have an educational effect, with continuous updating of drug therapy in clinical practice.
Nowadays, costs are very much in focus in the hospital sector of health care. The 
presumed outcome of reducing DRPs – less drug-related morbidity – generates savings to 
society as a whole. The added value will be avoidance of hospital admission, a shorter stay in 
hospital, more beneficial use of drugs and more optimal use of other health care services. 
However, since the savings are often not directly connected to the specific hospital involved it 
may be difficult to convince hospital administrators that investing money in prevention of 
DRPs is worthwhile in the long run, since their primary task is to look after their own budget. 
However, by applying a broad perspective, and considering society as a whole, it appears that 
investing money in preventing DRPs is worthwhile and cost effective in the long term. 
Studies, although not in Europe, have shown that the costs of incorporating clinical 
pharmacists into multidisciplinary hospital teams give a net hospital cost benefit (41;42;93-
98). These findings provide circumstantial evidence that the introduction of clinical pharmacy 
practices in Norwegian health care may well contribute to savings in the public health care 
budget.
53
5.2.4 Priorities and advice (Aim IV)  
An important issue rarely studied is how pharmacists deal with DRPs. Although not 
surprising, our finding that DRPs of minor clinical significance are more often omitted from 
discussions than are DRPs of greater significance has not been reported before. Furthermore, 
to our knowledge, our study is the first to investigate the reasons for pharmacists not 
intervening in the case of an identified DRP. The main reason was the setting of priorities, an 
important factor for hospital efficiency. Ideally, all DRPs should be addressed, but in clinical 
practice it is necessary to be pragmatic, to focus first on major issues. In our study, the 
grouping of reasons for the pharmacists not discussing a DRP – no priority, not relevant, 
others – was somewhat inaccurate. Nevertheless the data demonstrate how the pharmacists 
reason and carry out their work on DRPs.
Another issue related to priority concerns patient characteristics. Why was it that 
patients with several DRPs, who exhibited many potential risk factors for DRPs, and who 
were taking many drugs were less likely to have all their DRPs brought up for discussion by 
the pharmacist than other patients were? Was this because the pharmacists took the view that 
“this is too much to deal with”? We have not found any other study looking into how clinical 
pharmacists reason when encountering DRPs. In any case, it is important to tackle inequalities 
in delivery of service, and further studies are needed to provide a better understanding of this 
issue.
Advice from pharmacists on the multidisciplinary team was well received by the 
physicians. The majority of the DRPs brought up by the pharmacist were acted upon. The 
rates of acceptance were in line with the results from other studies (99-104). Could it be that, 
without proposals from the clinical pharmacist, the physicians would have taken the same 
decisions regarding drug therapy? If so, the contribution of clinical pharmacists is 
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overestimated. However, given the magnitude of DRPs identified, the nature of the 
interventions, and the wide variation of addressed drugs, it is likely that the handling of DRPs 
reflects the pharmacists’ focus on drugs and that the presence of pharmacists on the team 
creates a general alertness to drug issues among all members of the team.  
Worldwide, there is a call for the pharmacist profession to help improve drug safety 
and outcomes (46;67;105). Pharmacist workforce shortage is a problem in Norway, but the 
clinical pharmacy discipline, which is a branch of the pharmacy profession, is popular among 
young pharmacists. In Norway today, it is a drawback that the undergraduate pharmacy 
curriculum does not focus on clinical pharmacy. However, plans have been put forward to 
start a new Masters programme in clinical pharmacy at the School of Pharmacy, University of 
Oslo. In line with this proposal, the University should make efforts to comply with the grass-
root demand to develop scientific competence in this area.  
5.2.5 Drug use in patients with renal impairment (Aim V)  
Renal risk drugs 
It is possible that many patients with moderate to minor renal impairment are treated 
inappropriately. Mild renal impairment is often overlooked, and the result may be unfortunate 
drug use and drug dosages. This could exacerbate the renal impairment and lead to ADRs. For 
many drugs renal elimination is important. This is both recognised and addressed in the 
Summary of Product Characteristics, in drug catalogues and in separate lists of drugs with 
rules for caution in cases of renal impairment. However, as our study has shown, when it 
comes to clinical practice, this information seems to be overlooked or ignored. Certainly, in 
some cases, the use of renal risk drugs could be defended, and they might have been used 
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deliberately. For example, some of the drugs would have been prescribed to prevent 
cardiovascular events and in these situations the risk of worsening renal function is a 
calculated one. However, some drug use could also be due to ignorance – it is easy to forget 
rules of caution when it comes to common drugs that produce few adverse events. When a 
patient presents with mild to moderate renal impairment, various questions concerning drug 
therapy should be raised: Which drugs and which doses are optimal? Should the drug be 
continued, or should one switch to another drug? In hospitals, where patients stay for only a 
short time, a wise solution would probably be to continue the current treatment unless the 
renal function becomes severely deteriorated. On the other hand, it is easier to elaborate on a 
patient’s renal function in hospital, and recommendations for well-founded drug changes 
could be included in the discharge report.
It has been shown that some drugs associated with rules of caution also are 
renoprotective in the long term (106-109). These drugs – ACE inhibitors, angiotensin II 
antagonists, calcium channel blockers and the statins – were frequently used by the patients in 
our study and were often involved in DRPs (Figure 5.2). These renoprotective drugs are 
challenging to handle, since the balance between efficacy and adverse effects is a fine one.  
It could also well be that other renal risk drugs (i.e. other than those mentioned above) 
may have a positive or a negative long-term impact on renal function. This can only be 
clarified by future epidemiological studies in patients with renal impairment. Furthermore, 
little is known about the effects of a combination of renal risk drugs – one would assume that 
two renal risk drugs would have synergistic or additive negative effects on the kidney.  This 
lack of knowledge is a problem for clinicians treating patients with minor to moderate renal 
impairment. More research in this area is needed to enable reliable advice on drug use in these 
patients. 
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Figure 5.2 Use of renal risk drugs divided into a) those that also are renoprotective and b) 
other renal risk drugs. The figure also shows the relationship to occurrence of DRPs for the 
two groups.
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Methodological considerations 
The Cockcroft-Gault equation is regarded to be a rough, but good bedside estimate of renal 
status in the elderly. Since many of our patients were old this seemed to be a good option, and 
in the initial analysis GFR was estimated by this method for those patients where information 
on weight was available. During the study the multidisciplinary health team evaluated 
whether the patients had significant clinical reduction of renal function, defined as GFR less 
than 50 ml/min (see Methods 3.3). This evaluation was based on either the calculation of 
renal function from the Cockcroft-Gault formula or, on a pragmatic clinical approach í
grading only on the basis of SCr levels í for those patients whose weight was not known. 
Using SCr only is a method commonly used by physicians, and when the SCr is obviously 
raised, this situation creates awareness with regard to drug handling. However, an estimation 
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based on SCr alone is not unproblematic, since SCr is not a good indicator in very old 
patients. Progressive reduction of muscle mass with ageing reduces the production of 
creatinine, and this may parallel a real decrease in renal function. The result is that the SCr-
level remains unchanged and a renal impairment will be masked (110;111). The initial 
analyses revealed a marked inconsistency between the groups analysed by these two ways; 
Cockcroft-Gault and SCr alone (data not given).  The data indicated that some patients in the 
SCr group might have had more severe renal impairment than estimated. Struggling with this 
selection bias we realised that the MDRD method, which has become increasingly used in 
recent years, was a good and reliable method for estimating GFR. Therefore, retrospectively 
we decided to use that method on the whole patient population. 
The GFR grading achieved by the two methods (the initial Cockcroft-Gault/SCr and 
the retrospective MDRD) differed to some degree, but the difference was not pronounced. 
There was a trend towards more severe grading when applying the MDRD formula (Figure
5.3). In general, however, the findings with regard to drug use were the same whether the 
analyses were made with renal impairment diagnosed on the basis of the MDRD formula or 
by the other method combining the Cockcroft-Gault equation with clinical evaluation of SCr. 
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Figure 5.3 Number of patients and mean SCr values in patients in various stages of RI*, 
applying different methods. Three ways of grading renal impairment (RI) are shown: a) 
calculation of GFR by the Cockcroft-Gault equation (CG), b) estimation of GFR by clinical 
evaluation of SCr, c) calculation of GFR by the MDRD formula. (Only the MDRD formula 
was used for the calculations in Paper III).
* see Table 3.2 
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5.2.6 Drug interactions (Aim VI) 
Drug interactions (DDIs) may be responsible for a substantial number of hospital admissions 
(18;112-114). In hospitals many new drugs are added and many new DDIs are introduced 
(115). The presence of drug interactions in a patient’s drug regimen is common but the 
number of clinically serious DDIs is reported to be low (116-119). This agrees with our 
findings.
In many countries sophisticated computer software is available for screening 
medication profiles with the objective of detecting DDIs. These databases are adapted to the 
national market, that is to say, they include only drugs with marketing authorisation in the 
country concerned. In hospital it is not uncommon to use non-licensed products. Such drugs 
are either imported from other countries or prepared by special service production; they are 
not included in the database constructed to detect drug interactions. Of course, global drug 
interaction screening programmes (120) could have been used, but in clinical practice 
prescribers are most familiar with the brand-name, not the generic name of the drug. Hence 
computer software adapted to the national market is preferable, since this will be the most 
user-friendly tool.
Although DDIs can be discovered by reviewing the patients’ drug regimen by means 
of computer screening programmes, these programmes come up with a large proportion of 
theoretical alerts that may be of only minor clinical significance. These DDI alerts are not 
necessarily meaningless or a waste of time, considering that DDIs constitute an important 
cause of ADRs, but it is necessary to have health care workers who have the skill to 
understand and combine clinical and pharmaceutical information in order to interpret the 
outcome of the screening. Properly used, a computer screening programme used could reduce 
the magnitude of severe interactions (121). Such a screening programme should never be used 
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alone, however, since computer programmes are not flexible in the sense of being able to 
evaluate clinical information regarding health status and individual patient characteristics. 
Our study demonstrated this point and showed that many DDIs signalled by computer 
screening to be severe were in fact introduced intentionally and probably to the benefit of the 
patients.  
Important interactions may also arise as a result of the use of complementary and 
alternative medicines and normally these interactions are not included in computerised 
surveillance programmes. Herbal medicines are widely used (122), and a recent study found 
that almost one-third of current users of herbal medicines were at risk of a herb-drug 
interaction (123). Neither do the computer screening programmes include drug interactions 
linked to alcohol or smoking. Thus, for example, if precautions are not taken, patients using 
theophylline may experience severe ADRs if they stop smoking, caused by an elevated level 
of serum theophylline. By contrast, clinical evaluation could have picked up that a stable 
smoking-drug interaction was going to be disturbed. Owing to the lack of comprehensive 
summaries,  interactions other than drug-drug interactions are left to be judged by the 
prescriber, an often difficult and challenging task.
5.3 Internal and external validity 
This section addresses the internal and external validity of the study. Associations found in 
the study must be a result of causation, chance, bias or confounding (124). There are two 
kinds of errors that could influence the conclusions, random errors (chance) and systematic 
errors (bias). Precision (lack of random error) can be improved by enlarging the study sample 
or by modifying the study design. Our study was carried out in clinical practice and the design 
had to be adapted to daily hospital routines. This strengthens the external validity of the study. 
The inclusion of about 800 patients was estimated to be abundant to make in-depth analyses 
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and draw valid conclusions – for the whole material and for a number of subgroups. On the 
basis of the above, we also estimated that it would be sufficient to let every 6th patient 
undergo evaluation by the quality assessment team – and let every 4th patient be interviewed 
by clinical pharmacists.  
5.3.1 Internal validity 
Various biases that could reduce the validity of results are discussed. The main types of 
systematic errors are selection bias, information bias and confounding (124). 
Selection bias 
Selection bias results from the way patients are selected into the study, the problem being that 
the patients might not be representative of the population we want to study (124). All patients 
admitted to the participating departments were eligible for inclusion and selection bias should 
thus have been avoided. In order to prevent preferential selection of patients to the quality 
assessment, we used random selection; every 6th patient recruited to the study would be 
assessed by the quality team. This implies that our results are presumed to be representative 
for patients admitted to departments in Norwegian hospitals. 
In Paper III a crucial objective was to grade renal function. The original data recording 
form had a column for SCr values. The SCr values were to be used to estimate GFR since our 
primary aim was to look at reduced renal function as a risk factor for DRPs. However, the 
data collectors sometimes omitted to note the exact SCr value if the patient was undoubtedly 
considered to have normal kidney function on the basis of laboratory tests and medical 
history. After the data collection, we reconsidered the method of calculating renal function 
and decided to use the MDRD formula instead of the Cockroft-Gault formula. This was 
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because the former method of evaluation has been increasingly recommended by 
nephrologists in recent years. By using the MDRD method we were able to calculate GFR for 
the majority of the enrolled patients, but 19 patients had to be excluded from the analysis 
owing to lack of exact SCr values. These 19 patients were distributed between all hospitals 
and all departments, indicating that selection bias would not be induced by this omission. 
Thus it is likely that the results as regards both the occurrence of renal impairment and drug 
use are valid for other similar departments.  
Information bias 
Information bias results from the way information is obtained (124). Information on the 
patients’ drug regimens was collected from medical charts, medical records and data gathered 
on the physicians’ rounds, and sometimes also after pharmacists had interviewed the patients. 
In our study, the patients’ drug profiles at admission, that is to say, the drugs they had been 
using at home, were ascertained through normal hospital admission procedure. The patients 
were interviewed by physicians in the admission unit and the information obtained was 
recorded by hand on the medicine chart. Several studies have shown that this way of 
acquiring information on drugs can be imperfect (125-129). Often, chronic medication not 
detected at admission but recognised later by ward staff is added to the medicine chart. Since 
the medication chart was one of the sources of information for the data collectors, a pertinent 
question is whether the recognised drug list was correct. In a subproject of our study, 
pharmacist interviews with patients on their medication (130) revealed additional DRPs, some 
of which related to drug use not identified at admission. Only 96 of the 827 patients were 
interviewed, however. The interviewed patients were randomly chosen for interview, which 
implies that, in the case of the patients who were not interviewed, some of the chronic 
medication being used may have been missed and, as a consequence, also some of the DRPs. 
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However, this bias probably did not influence the number of patients having DRPs, since the 
majority of patients (i.e. 81% of the patients) had already been identified as having DRPs.   
The procedure whereby DRPs are allocated to specific categories also entails risk of 
misclassification. The allocation was made by the data collector. It is possible that the 
evaluation of a DRP by one data collector may differ from that made by another, implying 
that the assignment of the DRP to the different categories may not have been done uniformly. 
This can be demonstrated by an example: A patient is admitted to hospital with chronic 
obstructive pulmonary disease (COPD). He uses prednisolone tablets daily. Prednisolone was 
prescribed half a year ago in connection with a previous hospital stay after which the patient 
was discharged with a one week treatment with prednisolone. Despite the intention of a 
limited period of treatment, prednisolone was still being used. This DRP could be allocated to 
either “unnecessary drug” or to “no further need”. To avoid this type of misclassification the 
data collectors discussed possible wrong classifications before starting the study itself. 
Although some degree of misclassification might still have taken place, this should not have 
occurred for the DRP category “drug interaction”, because all allocations to that category 
were based on explicit lists of interactions. Moreover, for the majority of DRPs, 
misclassification was not a real problem and, hence, this type of information bias is unlikely 
to have influenced the main results of the study.  
The degree to which pharmacists identify and bring up DRPs for discussion will 
depend on their experience in this connection (103). All the clinical pharmacists in our study 
were experienced and their clinical pharmacy service was a routine function. A new service 
introduced as a part of a research project and using inexperienced data collectors might have 
resulted in different intervention and response outcomes. The strength of using routine 
services for the research on pharmacist interventions implies that the results reflect daily 
practice and are little influenced by collection bias.
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Another strong point of our study was that it involved only few data collectors, all of 
whom had participated in the development of the study protocol and testing of the data 
collection forms. By choosing this design, we ensured that the data would be comparable and 
reliable.
Confounding
A confounding factor is a distortion of an exposure-outcome association brought about by the 
association of another factor with both outcome and exposure. The confounder needs to be a 
risk factor for the outcome, associated with the exposure under study, and must not be 
affected by the exposure or by disease (124). Confounding may be prevented by including 
randomisation in the study design. We used random selection to two subsets of patients for 
study, first to select patients for quality assessment and second to select patients for 
pharmacist interview (130). In this way we tried to avoid confounding. 
Confounding can also be corrected for in the analysis. In our study we addressed 
confounding by using multivariate analyses when examining the occurrence of DRPs. In 
Paper I logistic regression was carried out to find the relationship between DRPs and risk 
factors. The selection of risk factors included were the ones most often mentioned in the 
literature giving rise to heightened risk of DRPs. Socio-demographic factors like education, 
domicile and civil status are other factors that might influence level of risk. Such factors have 
been reported to have an impact on morbidity and mortality (131;132). However, no data 
were collected on these factors, which therefore could not be evaluated.
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5.3.2 External validity  
A study is externally valid if it can produce valid results beyond the subjects in the study. Our 
study was conducted in 2002 in eight departments distributed between five hospitals in 
Norway. Since it is a multicentre study undertaken in different geographical areas, the results 
could probably be translated to other departments of internal medicine and rheumatology in 
Norway and, furthermore, to a large extent to hospitals in other countries.
5.4 Implications and further research 
The results from papers I-IV in this thesis raise a number of pharmacotherapeutic issues in 
relation to drug use in hospital. Particular focus should be placed on the transition to primary 
care. At the hospital new and potent drugs are often added to the drug regimens and, in 
addition, other drugs withdrawn. Consequently, it is of major and practical interest what 
happens after the patients are discharged from hospital. This is an area of concern. Seamless 
care – safe patient transition from hospital to home, implying better communication between 
hospital and primary care – has been focused on and demanded (133). So far, research on this 
issue has dealt mainly with the avoidance of medical errors and compliance. The follow-up on 
DRPs should also be addressed.
6 Conclusions 
We have demonstrated that the majority of patients admitted to hospitals have DRPs, usually 
each patient has several. Furthermore, we have shown that clinical pharmacists function as 
catalysts in the multidisciplinary team by initiating the identification and solving of DRPs. 
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We have also pointed out that explicit lists of drug interactions and of drugs that should be 
used with caution in patients with renal impairment are long and comprise many common 
drugs that seldom create problems. Furthermore, these lists are not precise enough as regards 
clinical significance to be used as a routine in clinical practice.  
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